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'~ '~ ' ]  Aseessment of Maximal Microvascular Dilator 
Capacity In Myocardial Regions With Normal Row 
Reserve: Observations in Patients With Stable IHD 
Gordon S. Huggins, Hal A, Skopicki, Stephen A. Abraham, Nathaniel 
M. Alpert,, Alan J. Fischman, Richard C. Pastemak, Henry Gewirtz. 
Massachusetts General Hospital, Boston, MA 
Prior studies of coronary flow reserve (CFR) in patients (Pts) with ischemic 
heart disease (IHD) have compared CFR in vessels free of hemodynamically 
significant stenosls with that of normal vessels of normal volunteers. Im- 
paired flow reserve in normal coronary vessels of IHD Pts has been reported 
by some but not others. We tested the hypothesis in IHD Pts that vascular 
zones with normal resting blood flow and flow reserve, nevertheless, may 
have reduced maximal microvessel dilator capacity. Measurements of hemo- 
dynamics and regional myocardial blood flow (RMBF mt/min,/g; PET N-13 
ammonia method) were made at rest and at maximal adenosine (Ado- 140 
/zg/Kg/min. x 6 rain IV) in 21 Pts with IHD (18 male, 3 female; age 65:1:8 
yrs (Mean -;- SD) and 9 normal volunteers (WNL; 5 male, 4 female; age 44 
+ 13. Only regions with flow reserve > 2.5 were used (IHD = 35, WNL = 26). 
Results: 
RMBFrest RMBFado ADO/REST RESISTado 
IHD 0.73 4. 0,28 2,22 ± 0.88 3.08 ± 0,30 65 4. 01 
WNL 0.89 ± 0.14" 3.49 ± 0.81 * 3.98 ± 1.02" 34 ± 10* 
• P < 0.OOl vs IHO, RESIST = MAP/RMBF. 
Resting heart rate and systolic blood pressure were comparable (IHD = 
59 4- 14 and 144 4- 23, respectively vs WNL = 66 4- 9 and 132:1: 19). 
Systolic pressure with Ado also was similar (IHD = 137 ± 20 vs WNL = 129 
:E 17) though HR with Ado was higher (P < 0.05) in WNL (100 -;- 33) vs 
IHD (65 ± 19), In a subset of 12 IHD Pts reduction of LDL cholesterol {167 
4 to 83 4- 9 mg/dl P < 0.001) with 4 mo of simvastatin failed to improve 
maximal microvascular dilation (RESISTado = 63 ± 8 to 63 :E 7). Thus in IHD 
Pts vascular regions with normal rest RMBF and normal flow reserve have 
reduced maximal microvascutar dilator capacity. Reduction of LDL below 100 
mg/dl does not correct his form of microvascutar dysfunction which may be 
endothelium independent. 
~ Contribution of Nitric Oxide to Bradykinin-lnduced 
Dilation of Human Coronary Resistance Vessels in 
Vivo 
Masaya Kato, Nobuo Sh;ode, Masafumi Hiraga, Akito Hiraoka, 
Nobuyuki Morishima, ShinJi Karakawa, Tego Yamagata, Hideo Matsuura, 
Goro Kajlyama. First Department of Internal Medicine, Himshima Universi~ 
Hireshirn~, Japan 
Bradykialn has been shown to induce endothelium.depandent dilation of 
human forearm resistance vessels In vivo. To investigate whether nitric ox- 
ide (NO) release contributes to bradykinin-lnduced vasedllstion of human 
coronary resistance vessels in vivo, we "=tudied the effect of inhibition of NO 
synthesis by Ne-monomsthyI-L-arginina (L-NMMA) on intracoronary infusion 
of bredykinin in 8 patients with normal coronary arteries. After baseline an- 
giography, incremental doses of bradykinin (0.5, 1.5, and 2.5 p.g/min for 2 
rain) were infused Into the left coronary artery. Then, L-NMMA (60 p, moVmin), 
a competitive antagonist of nitric oxide synthase, was infused. After another 
baseline anglography, incremental doses of bradykinln were infused again. 
Coronary blood flow (CBF) was derived from Doppler flow velocity and quan- 
titative angiogrsphy. Coronary vascular esistance (CVR) was calculated as 
mean arterial pressure divided by CBF. Percent changes in CBF and CVR 
were as follows (mean -~ SO): 
eredykinln (/Jg/min) 
0.5 1.0 2,5 
CBF Before L-NMMA +47 4- 43%** +99 ± 75%* +134:1: 62%" 
After L-NMMA +21 4-18% +72 4. 64%* +107 4- 66%* 
CVR Before L-NMMA -30 =E 14%* -46 -4-19%" -56 ± 13%" 
Nter L-NMMA -17±8%" -40"¢- 17%* -49-;- 17%* 
*p < 0,01, **p < 0.05 vs Baseline 
L-NMMA reduced the I~seilne CBF by 18 4- 7% and increased the baseline 
CVR by 28 4- 17%, Bradykinin increased CBF and reduced CVR before 
and after L-NMMA infusion in dose-dependent manner, and the vasodilator 
response to bradyklnln after L-NMMA infusion was comparable to that before 
L-NMMA infusion. These data suggest that endothelium-derived NO may 
not contribute to bradykinin-inducod dilation of human coronary resistance 
vessels in vivo. 
• Blockade of ATP-Senaltive Potassium Channels 
Does Not Prevent Acetylchollne-induced Increase 
in Peripheral Blood Flow 
Fabrizio Tomal, Filippe Crea, Achille Gaspardone, Maria Cascarano, 
Luigi Chiariel]o, Pier A. Gioffr~. Divisione di Cardiechirurgia, Universit~ "for 
Vergata, Rome, Italy 
Both expadmentai nd clinical studies have shown that the increase in re- 
gional blood flow Induced by acetylcholina (ACh) is not completely prevented 
by inhibifors of the synthesis of endothellum-dedved nitric oxide. It is also 
known that stimulation of ACh-M2 receptors may open ATP-sensitive potas- 
sium channels (KATP) in myocytes, thus suggostlng that heir stimulation may 
also increase blood flow by opening K^Tp in vascular smooth muscle. The 
aim of this study was to assess the effects of ACh on the iliac artery blood flow 
pre and post glibenclamide (GI), an antagonist of KATp. TO this end, 6 patients 
without evidence of pedpherel vascular dlsease received Intra-iliac incremen- 
tal bolus inje~ii~s of ACh (50, 100 and 200 p.g) via a 5F femoral sheath, 
at the end of routine cardiac catheterization. All injections were repeated 90 
minutes after oral administration of GI (10 rng). Right lilac artery blood flow 
velocity using a 0,014-in Doppler guide-wire and arterial blond pressure were 
continuously recorded. Blood glucose levels, which decreased from 104 4- 
17 to 75 4-19 rag% (p < 0.05) after GI, were corrected by Lv. 10% dextrose 
pdor to repeat ACh injections. Arterial blood pressure did not show significant 
changes throughout the study. Average peak velocity values (cm/sec) were 
the following: 
Baseltne saline ACh 50 pg. ACh 100 PO ACh 200 pg 
Pre:-G/ 16=E3 18=E4 29±11" 32:E 9' 34±12" 
Post.GI 17±6 18±6 33:t:13, 34+14" 364-14 °
"p < 0.05 vs baseline and saline 
In man, the increase in iliac artery blood flow induced by ACh is not 
prevented by GI, thus suggesting that it is not mediated by activation of 
KAT~ channels, Of note, in contrast with some expodmental data, GI does not 
reduce basal blood flow, thus suggesting that KATp do not influence peripheral 
vascular tone. 
~ T h e  Estrogen Receptor Is Not Found in Classl¢,~l 
Human Coronary Artades 
Peter Collins, Mary Sheppard, Carolyn M. Beale, Mifch Dowser 1, National 
Heart & Lung Institute, Imperial College of Science, Technology and 
Medicine; 1 Royal Marsden Hospital. London, UK 
Estrogen relaxes a variety of isolated blood vessels including human core- 
nan/arteries, The mechanism of this vascular relaxation may or may not 
involve the classical estrogen receptor. We investigated the presence of es- 
trogen receptors in 28 epicardial coronary arteries (8 left main, 5 left anterior 
descending, 2 circumflex, 3 right coronary arteries) from 12 patients (mean 
age :t: SD; 44 -*- 13 years). There were 7 females and 5 mates all of which 
had died as a result of unexplained sudden adult death. We used a new 
mouse monoclonal antibody (1D5) diteclod against the N-terminal domain 
(A/B region) of the estrogen receptor in an immunohlstochemical assay (ER- 
IHA) which has been validated for tissues which have been paraffin wax 
embedded. Estrogen receptor *H-scores" were obtained from the ER-IHA 
after antigen retrieval using microwave treatment. The tissues studied were 
astmgon receptor negative, In particular, estrogen receptor was not found in 
either the endothelial layer or the vascular smooth muscle layer of the coro- 
nary artedes, Estrogen receptor was not found in female human coronary 
arteries, In conclusion, the classical estrogen reeeptor is not found in hu- 
man coronary arteries using this monoclonai antibody. Relaxation responses 
of these vessels to estrogen are unlikely to be via the classical estrogen 
receptor. 
